KOL mapping in Saudi Arabia's oncology market is a strategic intelligence programme — not a database search. With fewer than 200 specialist oncologists driving the majority of prescribing and treatment protocol decisions across the Kingdom, identifying the right physicians, understanding their influence networks, and engaging them at the right moment in your launch timeline is the single highest-ROI commercial activity a pharma or biotech team can execute in KSA.
BioNixus has delivered KOL mapping and stakeholder engagement programmes across MENA since 2012, from offices in London and Cairo. What distinguishes our approach is the integration of KOL identification with hospital-level and department-level consumption data — connecting influence mapping directly to prescribing reality.
Saudi Arabia's oncology landscape concentrates prescribing authority within a small number of high-influence institutions:
The dominant oncology centre in Riyadh. A small group of KFSH&RC physicians set treatment protocol standards that flow through the entire public hospital system. BioNixus tracks oncology consumption at department level within KFSH&RC — enabling us to map not just who the KOLs are, but which physicians drive the highest actual prescribing volume within the institution.
Operates a parallel formulary and procurement system with their own oncology physician community and independent KOL dynamics. A KOL engagement strategy built only on MOH-system physicians will miss NGHA entirely.
King Abdullah Medical City, King Khalid University Hospital, and the growing private oncology sector — Saudi German Hospitals, Tadawi, and international affiliates — create a multi-tier physician landscape requiring separate mapping and engagement strategies at each tier.
National formulary inclusion decisions are heavily influenced by specific oncology physicians serving on MOH advisory committees. Identifying who holds these roles — and connecting that to their actual consumption influence — is a material market access lever that database searches alone cannot surface.
BioNixus is the only MENA specialist firm that integrates hospital-level and department-level pharmaceutical consumption data with KOL identification. This matters because influence and prescribing volume are not always the same thing.
A physician may publish prolifically and speak at conferences — high influence score — while practising in a low-volume department. Another physician may have a lower publication profile but drive the highest actual consumption of your product category in the Kingdom.
By overlaying KOL influence mapping with BioNixus's consumption data sourced from hospital procurement systems and pharmacy records, we produce a prioritisation matrix that reflects both influence and prescribing reality — ensuring your KOL engagement budget is allocated where it generates the highest commercial return.
We define the precise mandate perimeter: tumour type, treatment line, treatment modality, and target physician specialties. Simultaneously, BioNixus runs a preliminary analysis of hospital-level consumption data in the relevant therapy area — identifying the top-volume institutions and departments before the KOL identification phase begins.
The KOL long-list is built from parallel data sources:
Each physician is scored across five dimensions — producing a composite influence profile that reflects both visible reputation and actual clinical and commercial impact.
BioNixus conducts structured qualitative interviews with 15 to 25 physicians per therapy area — conducted in Arabic or English according to physician preference. Primary validation surfaces emerging KOLs not yet visible in published data and reveals relationship dynamics within the KOL network that quantitative scoring alone cannot capture.
The final deliverable is a KOL engagement roadmap: who to engage first, in what format, with what message, at what stage of your launch or access timeline — with commercial rationale grounded in both influence data and consumption volume.
| Dimension | What We Measure |
|---|---|
| Scientific influence | Publication volume, citation index, trial PI roles, journal editorial positions |
| Clinical reach | Actual prescribing volume from consumption data, institutional tier, protocol authorship |
| Peer influence | Conference speaking, society leadership, mentorship and training roles |
| Commercial influence | Advisory board participation, formulary committee membership, guideline authorship |
| Digital presence | Medical media commentary, webinar activity, professional network engagement |
| Tumour Type | Notes |
|---|---|
| Breast cancer | Highest female cancer incidence in GCC; strong academic community at KFSH&RC and KAMC |
| Haematological malignancies | AML, CLL, multiple myeloma — concentrated expertise at KFSH&RC |
| Colorectal cancer | Rapidly growing incidence; key GI oncology community across Riyadh and Jeddah |
| Lung cancer | Growing specialist community with improved CT screening access |
| Rare tumours and orphan oncology | Saudi Arabia's genetic disease burden makes it a priority rare oncology market |
| Immuno-oncology and CAR-T | Emerging specialist community concentrated at KFSH&RC |
| Biosimilar oncology | Separate KOL mapping for biosimilar adoption dynamics and reference biologic defence |
BioNixus has delivered KOL mapping and consumption data programmes across MENA since 2012.
Proposals within 48 hours. London and Cairo offices.